Oxford University Hospitals (OUH) NHS Foundation Trust, North Bristol NHS Trust, and University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are now evaluating a cutting-edge Artificial Intelligence (AI) diagnostic system designed to enhance prostate cancer diagnosis.
In a collaborative project spearheaded by the University of Oxford, the ARTICULATE PRO study at the Nuffield Department of Surgical Sciences has achieved a new milestone.
The deployment of AI in the prostate cancer pathway has now expanded to three trusts, utilising the Paige Prostate Suite in the live clinical workflow at these hospital sites.
Each participating hospital employs different digital pathology scanners and information systems, serving diverse patient populations.
However, all three trusts are integrating Paige’s AI applications into their standard care practices to assess potential improvements in patient outcomes amid the increasing prevalence of prostate cancer.
The Paige Prostate Suite is a sophisticated diagnostic AI system comprising three applications that assist pathologists in detecting, grading, and measuring tumours in prostate biopsies and tissue samples.
Pathologists at these hospitals are examining how the Paige Prostate Suite affects clinical decision-making, pathology service delivery, and resource utilisation in a real-world setting.
This comprehensive study allows for a thorough evaluation of Paige’s AI technology’s impact on patients, histopathologists, and hospital systems in the context of prostate cancer diagnosis.
Funded by the Accelerated Access Collaborative (AAC) Artificial Intelligence in Health and Care Award, and overseen by the Department of Health and Social Care, the ARTICULATE PRO study’s latest achievement marks significant progress.
Professor Clare Verrill, OUH Cellular Pathology Consultant, Associate Professor, and Principal Investigator of ARTICULATE PRO, emphasised the patient-centric nature of the project: “The central focus of ARTICULATE PRO is patients.
We are striving towards our goal to safely and effectively ensure they benefit the most from powerful AI technology.
With the multisite live use of The Paige Prostate Suite, we can systematically study benefits to patients in clinical settings.”
Dr. Jon Oxley, uropathologist and Bristol lead of ARTICULATE PRO, highlighted the significance of this advancement: “I have studied the disease and progression of prostate cancer in clinical research for over 25 years.
It is a significant advancement that Paige’s AI system has achieved a level of validation and performance that allows safe and effective live clinical use.
Using this system alongside our standard of care has the promise to increase efficiency and improve reproducibility of results for patients.”
Dr. Bidisa Sinha, uropathologist at UHCW, shared insights on the potential benefits of AI in pathology: “We believe AI can help to improve the accuracy and consistency of grading cancer and assist in detecting small areas of cancer which are easy to miss.
This is world-leading research being carried out at UHCW. We are proud to be a global leader in the field of digital and computational pathology.”